Michel Henry-Amar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6872850/publications.pdf

Version: 2024-02-01

121 10,705 58
papers citations h-index

123 8666
times ranked citing authors

30922

102

g-index

123 all docs 123
docs citations

#	Article	IF	CITATIONS
1	Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer, 1994, 73, 2680-2686.	4.1	1,719
2	Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group Journal of Clinical Oncology, 1996, 14, 869-877.	1.6	558
3	Leukemia Following Hodgkin's Disease. New England Journal of Medicine, 1990, 322, 7-13.	27.0	486
4	Malignant Tumors Occurring after Treatment of Aplastic Anemia. New England Journal of Medicine, 1993, 329, 1152-1157.	27.0	445
5	Chemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin's Disease. New England Journal of Medicine, 2007, 357, 1916-1927.	27.0	412
6	Involved-Field Radiotherapy for Advanced Hodgkin's Lymphoma. New England Journal of Medicine, 2003, 348, 2396-2406.	27.0	301
7	Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly Journal of Clinical Oncology, 1990, 8, 272-279.	1.6	248
8	Combined-Modality Therapy for Clinical Stage I or II Hodgkin's Lymphoma: Long-Term Results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials. Journal of Clinical Oncology, 2006, 24, 3128-3135.	1.6	216
9	Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. British Journal of Haematology, 1996, 93, 731-736.	2.5	213
10	Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Annals of Oncology, 2006, 17, 1749-1760.	1.2	171
11	Macroscopic lymph-node involvement and neck dissection predict lymph-node recurrence in papillary thyroid carcinoma European Journal of Endocrinology, 2008, 158, 551-560.	3.7	164
12	Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors Journal of Clinical Oncology, 1988, 6, 239-252.	1.6	160
13	Comparison of High-Dose Therapy and Autologous Stem-Cell Transplantation With Conventional Therapy for Hodgkin's Disease Induction Failure: A Case-Control Study. Journal of Clinical Oncology, 1999, 17, 222-222.	1.6	147
14	Prognostic factors in primary gastrointestinal non-Hodgkin's lymphoma. A multivariate analysis, report of 106 cases, and review of the literature. Cancer, 1989, 64, 1208-1217.	4.1	142
15	Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood, 2003, 103, 1222-1228.	1.4	140
16	A multivariate analysis of prognostic factors in early stage hodgkin's disease. International Journal of Radiation Oncology Biology Physics, 1985, 11, 23-30.	0.8	138
17	Pericarditis and myocardial infarctions after Hodgkin's disease therapy. International Journal of Radiation Oncology Biology Physics, 1991, 21, 447-449.	0.8	129
18	Late psychosocial sequelae in Hodgkin's disease survivors: a French population-based case-control study Journal of Clinical Oncology, 1996, 14, 2444-2453.	1.6	125

#	Article	IF	CITATIONS
19	Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials. Lancet Haematology,the, 2015, 2, e492-e502.	4.6	123
20	Osteosarcoma: chemotherapy-induced changes at MR imaging Radiology, 1992, 182, 839-844.	7.3	116
21	Descriptive epidemiology of cerebral gliomas in France. Cancer, 1997, 79, 1195-1202.	4.1	114
22	Nebulized versus intravenous albuterol in hypercapnic acute asthma. A multicenter, double-blind, randomized study American Journal of Respiratory and Critical Care Medicine, 1994, 149, 1466-1470.	5.6	112
23	Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma. Human Pathology, 2007, 38, 212-219.	2.0	109
24	Clinical Relevance of Single-Photon Emission Computed Tomography/Computed Tomography of the Neck and Thorax in Postablation 131l Scintigraphy for Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2075-2084.	3.6	104
25	A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial Journal of Clinical Oncology, 1994, 12, 279-287.	1.6	102
26	Causes of death after therapy for early stage Hodgkin's disease entered on EORTC protocols. International Journal of Radiation Oncology Biology Physics, 1990, 19, 1155-1157.	0.8	100
27	Premature Ovarian Failure and Fertility in Long-Term Survivors of Hodgkin's Lymphoma: A European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Étude des Lymphomes de l'Adulte Cohort Study. Journal of Clinical Oncology, 2012, 30, 291-299.	1.6	99
28	Rotavirus Carriage, Asymptomatic Infection, and Disease in the First Two Years of Life. I. Virus Shedding. Journal of Infectious Diseases, 1984, 149, 667-674.	4.0	98
29	Effectiveness of Immunosuppressive Therapy in Older Patients with Aplastic Anemia. Annals of Internal Medicine, 1999, 130, 193.	3.9	97
30	Gonadal Function in Males After Chemotherapy for Early-Stage Hodgkin's Lymphoma Treated in Four Subsequent Trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Étude des Lymphomes de l'Adulte. Journal of Clinical Oncology, 2007, 25, 2825-2832.	1.6	96
31	Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC–GELA H8 randomised controlled trial. Lancet Oncology, The, 2009, 10, 1160-1170.	10.7	96
32	Quality of life and home enteral tube feeding: a French prospective study in patients with head and neck or oesophageal cancer. British Journal of Cancer, 2000, 82, 263-269.	6.4	89
33	Long-term quality of life after breast cancer: a French registry-based controlled study. Breast Cancer Research and Treatment, 2011, 129, 125-134.	2.5	89
34	Long-term toxicity of early stages of Hodgkin's disease therapy: The EORTC experience. Annals of Oncology, 1991, 2, 77-82.	1.2	88
35	Erythrocyte Sedimentation Rate Predicts Early Relapse and Survival in Early-Stage Hodgkin Disease. Annals of Internal Medicine, 1991, 114, 361-365.	3.9	86
36	Does malignant small round cell tumor of the thoracopulmonary region (askin tumor) constitute a clinicopathologic entity?. An analysis of 30 cases with immunohistochemical and electron-microscopic support treated at the institute gustave roussy. Cancer, 1992, 69, 1012-1020.	4.1	86

#	Article	IF	CITATIONS
37	Health-related quality of life and sequelae in patients treated with brachytherapy and external beam irradiation for localized prostate cancer. Annals of Oncology, 1998, 9, 751-757.	1.2	86
38	One-Year Longitudinal Study of Fatigue, Cognitive Functions, and Quality of Life After Adjuvant Radiotherapy for Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 81, 795-803.	0.8	86
39	High Doses of Inhaled Corticosteroids in Unstable Chronic Asthma: A Multicenter, Double-blind, Placebo-controlled Study. The American Review of Respiratory Disease, 1989, 140, 167-171.	2.9	85
40	The EORTC treatment of early stages of hodgkin's disease: The role of radiotherapy. International Journal of Radiation Oncology Biology Physics, 1984, 10, 197-210.	0.8	84
41	Health-Related Quality of Life Among Long-Term Survivors of Colorectal Cancer: A Population-Based Study. Oncologist, 2011, 16, 1626-1636.	3.7	82
42	Sperm quality before treatment in patients with early stage Hodgkin's lymphoma enrolled in EORTC-GELA Lymphoma Group trials. Haematologica, 2009, 94, 1691-1697.	3.5	80
43	Risk of second primary cancer following differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 685-691.	6.4	79
44	Late Toxicity of Radiotherapy in Hodgkin's Disease—The Role of Fraction Size. Acta Oncológica, 1988, 27, 123-129.	1.8	76
45	Pulmonary evaluation of patients with osteosarcoma: roles of standard radiography, tomography, CT, scintigraphy, and tomoscintigraphy. American Journal of Roentgenology, 1984, 143, 519-523.	2.2	75
46	Five-year results of the E.O.R.T.C. randomized study of splenectomy and spleen irradiation in clinical stages I and II of Hodgkin's disease. European Journal of Cancer, 1981, 17, 355-363.	0.9	74
47	Survival after Hodgkin lymphoma. Cancer, 2009, 115, 1680-1691.	4.1	72
48	Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma. International Journal of Radiation Oncology Biology Physics, 2007, 67, 19-30.	0.8	71
49	Is neuro-ectodermal differentiation of Ewing's sarcoma of bone associated with an unfavourable prognosis?. European Journal of Cancer, 1995, 31, 307-314.	2.8	70
50	Long-term quality of life in premenopausal women with node-negative localized breast cancer treated with or without adjuvant chemotherapy. British Journal of Cancer, 2000, 83, 577-582.	6.4	69
51	Specific Controversies Concerning the Natural History of Renal Disease in Pregnancy. American Journal of Kidney Diseases, 1991, 17, 116-122.	1.9	67
52	Prognostic significance of erythrocyte sedimentation rate in clinical stages I-II of Hodgkin's disease Journal of Clinical Oncology, 1984, 2, 194-200.	1.6	65
53	Radiation-induced lung damage after thoracic irradiation for Hodgkin's disease: the role of fractionation. Radiotherapy and Oncology, 1995, 36, 211-217.	0.6	65
54	The EORTC trials for limited stage Hodgkin's disease. European Journal of Cancer, 1992, 28, 1847-1850.	2.8	64

#	Article	IF	CITATIONS
55	The achievements of the EORTC Lymphoma Group. European Journal of Cancer, 2002, 38, 107-113.	2.8	64
56	Long-term results of the E.O.R.T.C. randomized study of irradiation and vinblastine in clinical stages I and II of Hodgkin's disease. European Journal of Cancer, 1979, 15, 645-657.	0.9	62
57	Acute Leukemia After the Treatment of Hodgkin's Disease. Hematology/Oncology Clinics of North America, 1993, 7, 369-387.	2.2	62
58	Assessment of DNA damage induced in vitro by etoposide and two fungicides (carbendazim and) Tj ETQq0 0 0 r Molecular Mechanisms of Mutagenesis, 1997, 375, 205-217.	gBT /Over 1.0	lock 10 Tf 50 62
59	Late radiation injuries of the gastrointestinal tract in the H2 and H5 EORTC Hodgkin's disease trials: Emphasis on the role of exploratory laparotomy and fractionation. Radiotherapy and Oncology, 1988, 13, 61-68.	0.6	58
60	Rotavirus Carriage, Asymptomatic Infection, and Disease in the First Two Years of Life. II. Serological Response. Journal of Infectious Diseases, 1984, 149, 675-682.	4.0	52
61	DNA damaging effects of pesticides measured by the single cell gel electrophoresis assay (comet assay) and the chromosomal aberration test, in CHOK1 cells. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 1998, 419, 79-90.	1.7	52
62	Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin's Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-F Trial Blood, 2005, 106, 814-814.	1.4	46
63	Late relapse in early-stage Hodgkin's disease patients enrolled on European Organization for Research and Treatment of Cancer protocols Journal of Clinical Oncology, 1993, 11, 225-232.	1.6	43
64	Do Patients With Advanced Urothelial Carcinoma Benefit From Weekly Paclitaxel Chemotherapy? A GETUG Phase II Study. Clinical Genitourinary Cancer, 2009, 7, E28-E33.	1.9	43
65	Pregnancy in IgA Nephropathy, Reflux Nephropathy, and Focal Glomerular Sclerosis. American Journal of Kidney Diseases, 1987, 9, 334-338.	1.9	41
66	Polyploid megakaryocytes develop randomly from a multicompartmental system of committed progenitors Proceedings of the National Academy of Sciences of the United States of America, 1982, 79, 4410-4414.	7.1	40
67	Clinical relevance of gallium-67 scintigraphy in lymphoma before and after therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 176-184.	6.4	40
68	Evolution of erythrocyte sedimentation rate as predictor of early relapse in posttherapy early-stage Hodgkin's disease Journal of Clinical Oncology, 1988, 6, 596-602.	1.6	39
69	Histopathological predictive factors in Ewing's sarcoma of bone and clinicopathological correlations. Virchows Archiv A, Pathological Anatomy and Histopathology, 1986, 409, 627-640.	1.4	38
70	Prognostic value of DNA cytometry in 281 premenopausal patients with lymph node negative breast carcinoma randomized in a control trial. Cancer, 2000, 89, 1748-1757.	4.1	38
71	Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials. Haematologica, 2017, 102, 1748-1757.	3.5	38
72	Randomized clinical trial of post-operative radiotherapy versus concomitant carboplatin and radiotherapy for head and neck cancers with lymph node involvement. Radiotherapy and Oncology, 2008, 87, 164-172.	0.6	37

#	Article	IF	Citations
73	Radiation injurie of the gastrointestinal tract in Hodgkin's disease: The role of exploratory laparotomy and fractionation. Radiotherapy and Oncology, 1984, 2, 93-99.	0.6	33
74	ABVD or BEACOPP baseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)–Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial. European Journal of Cancer, 2017, 81, 45-55.	2.8	33
75	Parenthood in Survivors of Hodgkin Lymphoma: An EORTC-GELA General Population Case-Control Study. Journal of Clinical Oncology, 2012, 30, 3854-3863.	1.6	32
76	Urine mutagenicity and lymphocyte DNA damage in fruit growers occupationally exposed to the fungicide captan. Occupational and Environmental Medicine, 2003, 60, 910-917.	2.8	31
77	Cryopreservation, semen use and the likelihood of fatherhood in male Hodgkin lymphoma survivors: an EORTC-GELA Lymphoma Group cohort study. Human Reproduction, 2014, 29, 525-533.	0.9	30
78	Flow cytometry and quantitative immunohistochemical study of cell cycle regulation proteins in invasive breast carcinoma. Cancer, 2003, 97, 1376-1386.	4.1	29
79	Lymphocyte-rich classical Hodgkin lymphoma (LRCHL): clinico-pathological characteristics and outcome of a rare entity. Annals of Oncology, 2006, 17, 141-145.	1.2	28
80	Expression of $\hat{l}\pm$ V-associated integrin \hat{l}^2 subunits in epithelial ovarian cancer and its relation to prognosis in patients treated with platinum-based regimens. Journal of Molecular Histology, 2005, 36, 119-129.	2,2	27
81	Secondary solid malignant tumors occurring after bone marrow transplantation for severe aplastic anemia given thoraco-abdominal irradiation. Radiotherapy and Oncology, 1994, 30, 55-58.	0.6	25
82	Effects of Infused Intralipids on Neutrophil Chemotaxis during Total Parenteral Nutrition. Journal of Parenteral and Enteral Nutrition, 1986, 10, 596-598.	2.6	24
83	An alternating chemotherapy and radiotherapy combination for non-Hodgkin's lymphomas of unfavourable histologies: Feasibility and preliminary results. Radiotherapy and Oncology, 1985, 3, 133-138.	0.6	23
84	Poor Clinical Outcome of Patients Developing Malignant Solid Tumors after Bone Marrow Transplantation for Severe Aplastic Anemia. Leukemia and Lymphoma, 1992, 7, 419-423.	1.3	23
85	Follow-up thallium-201 scintigraphy after mantle field radiotherapy for hodgkin's disease. International Journal of Radiation Oncology Biology Physics, 1993, 25, 871-876.	0.8	23
86	Four ABVD and Involved-Field Radiotherapy in Unfavorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin's Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-U Trial Blood, 2005, 106, 813-813.	1.4	23
87	Therapeutic controlled trial in Ewing's sarcoma. European Journal of Cancer, 1977, 13, 1019-1023.	0.9	22
88	Quality control of involved-field radiotherapy in patients with advanced Hodgkin's lymphoma (EORTC) Tj ETÇ)q0,0,0 rg	BT /Overlock
89	Gallium-67 scintigraphy in lymphoma: is there a benefit of image fusion with computed tomography?. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 380-387.	6.4	21
90	Comparison of 36ÂGy, 20ÂGy, or No Radiation Therapy After 6 Cycles of EBVP Chemotherapy and Complete Remission in Early-Stage Hodgkin Lymphoma Without Risk Factors: Results of the EORT-GELA H9-F Intergroup Randomized Trial. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1133-1145.	0.8	21

#	Article	IF	Citations
91	Management of relapse and survival in advanced stage Hodgkin's disease: The EORTC experience. Annals of Oncology, 1991, 2, 63-66.	1.2	19
92	Low-Dose Involved-Field Radiotherapy as Alternative Treatment of Nodular Lymphocyte Predominance Hodgkin's Lymphoma. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1199-1202.	0.8	19
93	Relationship of histological subtypes to prognosis in early stage Hodgkin's disease: A review of 312 cases in a controlled clinical trial. European Journal of Cancer & Clinical Oncology, 1989, 25, 551-556.	0.7	18
94	Aberrant breakpoints in chronic myelogenous leukaemia; oncogenes and fragile sites. Human Genetics, 1986, 74, 447-448.	3.8	17
95	BCL-2/JH translocation in peripheral blood lymphocytes of unexposed individuals: Lack of seasonal variations in frequency and molecular features. International Journal of Cancer, 2003, 104, 695-698.	5.1	17
96	Lymphoblastic lymphoma in adults: a clinicopathological study of 34 cases treated at the Institut Gustave-Roussy. European Journal of Cancer & Clinical Oncology, 1988, 24, 1609-1616.	0.7	16
97	Title is missing!. Annals of Oncology, 1997, 8, 111-114.	1.2	16
98	Longâ€ŧerm fatigue in survivors of nonâ€Hodgkin lymphoma: The Lymphoma Study Association SIMONAL crossâ€sectional study. Cancer, 2019, 125, 2291-2299.	4.1	14
99	Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study. Health and Quality of Life Outcomes, 2019, 17, 115.	2.4	13
100	Alternating chemotherapy and radiotherapy combination for bulky stage I and II intermediate and high grade non-Hodgkin lymphoma: an update. Radiotherapy and Oncology, 1991, 20, 30-37.	0.6	12
101	Prognostic significance of tumour vascularisation on survival of patients with advanced ovarian carcinoma. Histology and Histopathology, 2009, 24, 425-35.	0.7	12
102	A phase II trial of radiochemotherapy with daily carboplatin, after induction chemotherapy (carboplatin and etoposide), in locally advanced nonsmall-cell lung cancer: Final analysis. International Journal of Radiation Oncology Biology Physics, 1997, 38, 163-168.	0.8	11
103	Urine mutagenicity of farmers occupationally exposed during a 1-day use of chlorothalonil and insecticides. International Archives of Occupational and Environmental Health, 2003, 76, 55-62.	2.3	11
104	Health outcomes of children fathered by patients treated with radioiodine for thyroid cancer. Clinical Endocrinology, 2009, 71, 880-883.	2.4	11
105	Linitis plastica after Hodgkin's disease. Lancet, The, 1993, 342, 57-58.	13.7	10
106	Biomonitoring of urine mutagenicity with the Ames test: improvement of the extraction/concentration method. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2002, 520, 199-205.	1.7	10
107	Therapeutic implications and sites of relapse predicted by elevated posttherapy erythrocyte sedimentation rate in early stage Hodgkin disease. American Journal of Hematology, 1991, 37, 253-257.	4.1	8
108	Rationale for ACE Inhibition in the Elderly: Treatment of Arterial Hypertension with Enalapril. Gerontology, 1987, 33, 9-16.	2.8	7

#	Article	IF	Citations
109	Analysis of T-cell-receptor variable gene segment usage in peripheral-blood lymphocytes of advanced cancer patients. International Journal of Cancer, 1993, 54, 60-67.	5.1	7
110	10 Treatment sequelae and quality of life. Best Practice and Research: Clinical Haematology, 1996, 9, 595-618.	1.1	6
111	Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: A French multicenter phase II study. Gynecologic Oncology, 2009, 115, 382-388.	1.4	6
112	Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: A Multicenter Phase II Trial. Gynecologic Oncology, 2010, 116, 312-316.	1.4	6
113	Does persistent fatigue in survivors relate to cancer?. Lancet Oncology, The, 2016, 17, 1351-1352.	10.7	6
114	Hodgkins disease. British Journal of Cancer, 2001, 84, 55-60.	6.4	5
115	Detection of DNA methylation adducts in Hodgkin's disease patients treated with procarbazine. Biomarkers, 1996, 1, 226-231.	1.9	4
116	Differential distribution of <i>vapA</i> â€positive <i>Rhodococcus equi</i> in affected and unaffected horseâ€breeding farms. Veterinary Record, 2017, 181, 145-145.	0.3	2
117	Randomized phase III study of gemcitabine and cisplatin (GC) versus dose dense methotrexate, vinblastine, doxorubicin and cisplatin (DD-MVAC) in the perioperative setting for patients with locally advanced transitional cell cancer of the bladder: The French GETUG/AFU V05 VESPER trial Journal of Clinical Oncology, 2018, 36, TPS530-TPS530.	1.6	2
118	Radiotherapy in Advanced-Stage Hodgkin's Lymphoma. Journal of Clinical Oncology, 2005, 23, 245-246.	1.6	1
119	Long term toxicity and fatigue after treatment for non-Hodgkin lymphoma (NHL): An analysis of twelve collaborative lymphoma study association (LYSA) trials, the Simonal Study Journal of Clinical Oncology, 2016, 34, 7518-7518.	1.6	1
120	Economic burden in nonâ€Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL crossâ€sectional study. Cancer, 2021, , .	4.1	1
121	Late Clonal Complications in Older Patients Receiving Immunosuppressive Therapy for Aplastic Anemia. Annals of Internal Medicine, 1999, 131, 633.	3.9	O